 Doxorubicin unresectable hepatocellular carcinoma prospective study addition verapamil prospective study safety efficacy addition oral verapamil intravenous Adriamycin doxorubicin management patients unresectable hepatocellular carcinoma HCC patients disease cirrhosis present patients adequate tissue overall median survival days Chemotherapy patients course treatment Partial response complete response patients patient patients Side effects chemotherapy present patients Death sepsis patients leukopenia Symptomatic myocardial dysfunction patient addition verapamil tumoricidal effect systemic Adriamycin HCC complications